1. |
Malik A, Hayat G, Kalia JS, et al. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol, 2016, 7: 64.
|
2. |
Mirrakhimov AE. Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management. Curr Med Chem, 2015, 22(16): 1963 - 1975.
|
3. |
Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev, 2014, 13(9): 883-891.
|
4. |
Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology, 2021, 26(4): 370-377.
|
5. |
Sharma N, Putman MS, Vij R, et al. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US Cohort. J Rheumatol, 2017, 44(11): 1612-1618.
|
6. |
Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med, 2019, 40(3): 561-572.
|
7. |
Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest, 2010, 138(6): 1464–1474.
|
8. |
Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med, 2016, 121: 91-99.
|
9. |
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ, 2016, 352: h6819.
|
10. |
American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med, 2000, 161(2): 646-664.
|
11. |
Hozumi H, Fujisawa T, Nakashima R, et al. Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis. J Rheumatol, 2019, 46(5): 509-517.
|
12. |
Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum, 2005, 52(8): 2439-2446.
|
13. |
Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity, 2005, 38: 383-392.
|
14. |
Rigby AL, Plit M, Glanville AR. Tacrolimus rescue therapy for severe respiratory failure in the anti-synthetase syndrome. Respirol Case Rep, 2014, 2(2): 70-72.
|
15. |
Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford), 2020, 59(5): 1084-1093.
|
16. |
Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford), 2015, 54(1): 39-44.
|
17. |
Takei R, Yamano Y, Kataoka K, et al. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig, 2020, 58(2): 83-90.
|
18. |
Nakazawa M, Kaneko Y, Takeuchi T. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheumatol, 2018, 37(3): 765-771.
|
19. |
Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep, 2018, 20(5): 27.
|